Research Areas

Biomarker Research
Diagnostic, Genomic Biomarker

At a Glance

- Status: Completed Consortium
- Year Launched: 2007
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Location: Europe

Abstract

More than 7,000 allogeneic hematopoietic stem cell transplants (HSCTs) are carried out each year in Europe alone, as a treatment for leukemia and lymphoma. Techniques and cure rates are improving, but the overall survival rate remains between 40-60 percent. This project will develop new proteomic, biological, and genomic tests and tools for early diagnosis and monitoring of patient response to novel therapeutics for the most severe complication of HSCTs, graft versus host disease (GvHD), and will bring to the clinic a new generation of diagnostics that will significantly improve HSCT therapy and patient outcome.

Mission

The consortium unites five European small to medium size enterprises (SMEs) with expertise and markets in genomic and proteomic testing, diagnostic assay development, and biochips, with clinical partners selected for their world-leading research in HSCTs and access to clinical samples and patient
The development of new diagnostic tests, new tools and non-invasive methods for the prevention, early diagnosis and monitoring for haematopoietic stem cell transplantation (STEMDIAGNOSTICS) - consortiapedia.fastercures.org

groups. The project will focus on the role of relevant genes and biomarkers associated with acute and chronic GvHD, using retrospective samples from established biobanks and prospective clinical trials to:

**Consortium History**

June 6, 2007: Start date
May 31, 2010: End date

**Financing**

The consortium is funded under the Sixth Framework Programme (Specific Targeted Research Project).

**Links/Social Media Feed**

Other website

**Sponsors & Partners**

Apetech Corporation
Association de Recherche Sur la Greffe De CSP (France)
Centre for Process Innovation
Charles University Prague
Forschungszentrum Fuer Umwelt Und Gesunheit, GMBH
IMGM Laboratories GMBH
The development of new diagnostic tests, new tools and non-invasive methods for the prevention, early diagnosis and monitoring for haematopoietic stem cell transplantation (STEMDIAGNOSTICS)

Updated: 04/15/2016